Matches in Nanopublications for { ?s ?p ?o <http://bio2rdf.org/drugbank:DB04872_nanopub.RAma2WBQ9O2n-2MxZh6cxQPe94PQ1mEY2AhMTpVB6xtXQ#assertion>. }
Showing items 1 to 15 of
15
with 100 items per page.
- drugbank:DB04872 type drugbank_vocabulary:Drug assertion.
- drugbank:DB04872 label "Osanetant [drugbank:DB04872]" assertion.
- drugbank:DB04872 seeAlso DB04872 assertion.
- drugbank:DB04872 description "Developed by Sanofi-Aventis (formerly Sanofi-Synthelabo), osanetant (SR-142801) is an NK3 receptor antagonist which was under development for the treatment of schizophrenia and other Central Nervous System (CNS) disorders. In a review of its R&D portfolio, the company announced in August 2005 that it would cease any further development of osanetant. This follows an earlier decision to discontinue development of eplivanserin for schizophrenia." assertion.
- drugbank:DB04872 identifier "drugbank:DB04872" assertion.
- drugbank:DB04872 title "Osanetant" assertion.
- drugbank:DB04872 drugbank_vocabulary:x-pubchemsubstance pubchem.substance:14765045 assertion.
- drugbank:DB04872 drugbank_vocabulary:x-pubchemcompound pubchem.compound:219077 assertion.
- drugbank:DB04872 drugbank_vocabulary:x-chemspider chemspider:189901 assertion.
- drugbank:DB04872 drugbank_vocabulary:x-cas cas:160492-56-8 assertion.
- drugbank:DB04872 drugbank_vocabulary:drugbank-id "DB04872" assertion.
- drugbank:DB04872 bio2rdf_vocabulary:x-identifiers.org DB04872 assertion.
- drugbank:DB04872 bio2rdf_vocabulary:uri "http://bio2rdf.org/drugbank:DB04872" assertion.
- drugbank:DB04872 bio2rdf_vocabulary:namespace "drugbank" assertion.
- drugbank:DB04872 bio2rdf_vocabulary:identifier "DB04872" assertion.